Antibiotice

Executive Summary

Antibiotice SA, founded in 1955 and headquartered in Iași, Romania, is a leading manufacturer of high-quality generic medicines with a portfolio exceeding 200 products. The company exports to over 70 countries, focusing on therapeutic areas such as anti-infectives, cardiovascular, oncology, and CNS medications. As a privately held company, Antibiotice has established a strong international presence, leveraging its vertically integrated manufacturing capabilities and stringent quality certifications to compete in the global generic drug market. The company's strategic investments in R&D and production capacity position it to capture growth opportunities in emerging markets and expand its product pipeline. Looking ahead, Antibiotice is expected to benefit from the increasing global demand for affordable generic drugs, particularly in Eastern Europe and Asia. The company's ability to navigate regulatory complexities and maintain high manufacturing standards will be key to sustaining its export momentum. However, competition from larger generic players and pricing pressures in mature markets pose risks. Overall, Antibiotice is well-positioned for steady growth, supported by its diversified product portfolio and expanding geographic footprint.

Upcoming Catalysts (preview)

• Q2 2026Launch of new generic products in oncology and CNS75% success
• H2 2026Expansion into new export markets in Asia and Africa65% success
• Q4 2026Strategic partnership for technology transfer or contract manufacturing60% success